IGFBP7在消化系统肿瘤中的研究进展
Research Progress of IGFBP7 in Digestive System Tumors
DOI: 10.12677/ACM.2023.134832, PDF,  被引量    科研立项经费支持
作者: 任怀静, 张梦迪, 李重杰：青海大学研究生院，青海 西宁；马臻棋*, 王学红：青海大学附属医院消化内科，青海 西宁
关键词: 消化系统肿瘤；IGFBP7；致癌机制；Digestive System Tumor； IGFBP7； Carcinogenic Mechanism
摘要: 消化系统肿瘤发病率及病死率高，对人类生命健康造成严重威胁。胰岛素样生长因子结合蛋白7 (insulin-like growth factor binding-protein 7, IGFBP7)是胰岛素样生长因子结合蛋白超家族中的一员，参与肿瘤的生长、增殖、侵袭、转移及小血管生成等过程，其在不同肿瘤中表现为激活或抑制肿瘤发生发展的双重生物学特性。IGFBP7有望成为消化系统肿瘤早期诊断、靶向治疗及评估预后的标志物，本文就近年来IGFBP7在消化系统中的研究进展及可能的致癌机制作一综述。
Abstract: The high incidence rate and mortality of digestive system tumors pose a serious threat to human life and health. Insulin-like growth factor binding protein 7 (IGFBP7) is a member of the insulin- like growth factor binding protein superfamily, which is involved in the growth, proliferation, inva-sion, metastasis and small angiogenesis of tumors. It has the dual biological characteristics of acti-vating or inhibiting tumor development in different tumors. IGFBP7 is expected to become a mark-er for early diagnosis, targeted treatment and evaluation of prognosis of digestive system tumors. This article reviews the research progress of IGFBP7 in digestive system and its possible carcino-genic mechanism in recent years.
文章引用：任怀静, 马臻棋, 王学红, 张梦迪, 李重杰. IGFBP7在消化系统肿瘤中的研究进展[J]. 临床医学进展, 2023, 13(4): 5894-5900. https://doi.org/10.12677/ACM.2023.134832

参考文献

[1] Smith, E., Ruszkiewicz, A.R., Jamieson, G.G. and Drew, P.A. (2014) IGFBP7 Is Associated with Poor Prognosis in Oesophageal Adenocarcinoma and Is Regulated by Promoter DNA Methylation. British Journal of Cancer, 110, 775-782. [Google Scholar] [CrossRef] [PubMed]
[2] Hojman, P., Gehl, J., Christensen, J.F. and Pedersen, B.K. (2018) Mo-lecular Mechanisms Linking Exercise to Cancer Prevention and Treatment. Cell Metabolism, 27, 10-21. [Google Scholar] [CrossRef] [PubMed]
[3] Jin, L., Shen, F., Weinfeld, M. and Sergi, C. (2020) Insulin Growth Factor Binding Protein 7 (IGFBP7)-Related Cancer and IGFBP3 and IGFBP7 Crosstalk. Frontiers in Oncology, 10, Article 727. [Google Scholar] [CrossRef] [PubMed]
[4] Hwa, V., Oh, Y. and Rosenfeld, R.G. (1999) The Insulin-Like Growth Factor-Binding Protein (IGFBP) Superfamily. Endocrine Reviews, 20, 761-787. [Google Scholar] [CrossRef] [PubMed]
[5] Akiel, M., Guo, C., Li, X., Rajasekaran, D., Mendoza, R.G., Robert-son, C.L., Jariwala, N., Yuan, F., Subler, M.A., Windle, J., Garcia, D.K., Lai, Z., Chen, H.H., Chen, Y., Giashuddin, S., Fisher, P.B., Wang, X.Y. and Sarkar, D. (2017) IGFBP7 Deletion Promotes Hepatocellular Carcinoma. Cancer Re-search, 77, 4014-4025. [Google Scholar] [CrossRef] 
[6] Bach, L.A. (2018) What Happened to the IGF Binding Proteins? Endocrinology, 159, 570-578. [Google Scholar] [CrossRef] [PubMed]
[7] Wang, S., Chi, K., Wu, D. and Hong, Q. (2021) Insulin-Like Growth Factor Binding Proteins in Kidney Disease. Frontiers in Pharmacology, 12, Article 807119. [Google Scholar] [CrossRef] [PubMed]
[8] López-Bermejo, A., Khosravi, J., Corless, C.L., Krishna, R.G., Diamandi, A., Bodani, U., Kofoed, E.M., Graham, D.L., Hwa, V. and Rosenfeld, R.G. (2003) Generation of An-ti-Insulin-Like Growth Factor-Binding Protein-Related Protein 1 (IGFBP-rP1/MAC25) Monoclonal Antibodies and Immunoassay: Quantification of IGFBP-rP1 in Human Serum and Distribution in Human Fluids and Tissues. The Jour-nal of Clinical Endocrinology and Metabolism, 88, 3401-3408. [Google Scholar] [CrossRef] [PubMed]
[9] Creemers, A., Ebbing, E.A., Pelgrim, T.C., Lagarde, S.M., van Et-ten-Jamaludin, F.S., van Berge Henegouwen, M.I., Hulshof, M.C.C.M., Krishnadath, K.K., Meijer, S.L., Bijlsma, M.F., van Oijen, M.G.H. and van Laarhoven, H.W.M. (2018) A Systematic Review and Meta-Analysis of Prognostic Bi-omarkers in Resectable Esophageal Adenocarcinomas. Scientific Reports, 8, Article No. 13281. [Google Scholar] [CrossRef] [PubMed]
[10] Kashyap, M.K., Pawar, H.A., Keerthikumar, S., Sharma, J., Goel, R., Mahmood, R., Kumar, M.V., Kumar, K.V., Pandey, A., Kumar, R.V., Prasad, T.S. and Harsha, H.C. (2013) Evaluation of Protein Expression Pattern of Stanniocalcin 2, Insulin-Like Growth Factor-Binding Protein 7, Inhibin Beta a and Four and a Half LIM Domains 1 in Esophageal Squamous Cell Carcinoma. Cancer Biomarkers, 12, 1-9. [Google Scholar] [CrossRef] 
[11] Huang, X., Hong, C., Peng, Y., Yang, S., Huang, L., Liu, C., Chen, L., Chu, L., Xu, L. and Xu, Y. (2019) The Diagnostic Value of Serum IGFBP7 in Patients with Esophageal Squamous Cell Carcinoma. Journal of Cancer, 10, 2687- 2693. [Google Scholar] [CrossRef] [PubMed]
[12] Li, X., Zhang, J., Wu, Y., Ma, C., Wei, D., Pan, L. and Cai, L. (2022) IGFBP7 Remodels the Tumor Microenvironment of Esophageal Squamous Cell Carcinoma by Activating the TGFβ1/SMAD Signaling Pathway. Oncology Letters, 24, Article No. 251. [Google Scholar] [CrossRef] [PubMed]
[13] Chen, Y.-B., Liao, X. Y., Zhang, J.B., Wang, F., Qin, H. D., Zhang, L., Shugart, Y.Y., Zeng, Y.-X. and Jia, W.-H. (2017) ADAR2 Functions as a Tumor Suppressor via Editing IGFBP7 in Esophageal Squamous Cell Carcinoma. International Journal of Oncology, 50, 622-630. [Google Scholar] [CrossRef] [PubMed]
[14] Zhao, Q., Zhao, R., Song, C., Wang, H., Rong, J., Wang, F., Yan, L., Song, Y. and Xie, Y. (2021) Increased IGFBP7 Expression Correlates with Poor Prognosis and Immune Infiltration in Gastric Cancer. Journal of Cancer, 12, 1343-1355. [Google Scholar] [CrossRef] [PubMed]
[15] Liu, Q., Jiang, J., Zhang, X., Zhang, M. and Fu, Y. (2021) Comprehensive Analysis of IGFBPs as Biomarkers in Gastric Cancer. Frontiers in Oncology, 11, Article 723131. [Google Scholar] [CrossRef] [PubMed]
[16] Sato, Y., Inokuchi, M., Takagi, Y., Otsuki, S., Fujimori, Y., Yanaka, Y., Kobayashi, K., Higuchi, K., Kojima, K. and Kawano, T. (2015) Relationship between Expression of IGFBP7 and Clinicopathological Variables in Gastric Cancer. Journal of Clinical Pathology, 68, 795-801. [Google Scholar] [CrossRef] [PubMed]
[17] Yoshioka, T., Shien, K., Namba, K., Torigoe, H., Sato, H., Tomida, S., Yamamoto, H., Asano, H., Soh, J., Tsukuda, K., Nagasaka, T., Fujiwara, T. and Toyooka, S. (2018) Anti-tumor Activity of Pan-HER Inhibitors in HER2-Positive Gastric Cancer. Cancer Science, 109, 1166-1176. [Google Scholar] [CrossRef] [PubMed]
[18] Liu, L., Yang, Z., Zhang, W., Yan, B., Gu, Q., Jiao, J. and Yue, X. (2014) Decreased Expression of IGFBP7 Was a Poor Prognosis Predictor for Gastric Cancer Patients. Tumour Biology, 35, 8875-8881. [Google Scholar] [CrossRef] [PubMed]
[19] Kim, J., Kim, W.H., Byeon, S.J., Lee, B.L. and Kim, M.A. (2018) Epigenetic Downregulation and Growth Inhibition of IGFBP7 in Gastric Cancer. Asian Pacific Journal of Cancer Pre-vention, 19, 667-675.
[20] Georges, R.B., Adwan, H., Hamdi, H., Hielscher, T., Linnemann, U. and Berger, M.R. (2011) The Insulin-Like Growth Factor Binding Proteins 3 and 7 Are Associated with Colorectal Cancer and Liver Me-tastasis. Cancer Biology & Therapy, 12, 69-79. [Google Scholar] [CrossRef] [PubMed]
[21] Shao, L., Huang, Q., Luo, M. and Lai, M. (2004) Detection of the Differentially Expressed Gene IGF-Binding Protein-Related Protein-1 and Analysis of Its Relationship to Fasting Glucose in Chinese Colorectal Cancer Patients. Endocrine-Related Cancer, 11, 141-148. [Google Scholar] [CrossRef] [PubMed]
[22] Li, Y., Xi, Y., Zhu, G., Jia, J., Huang, H., Liu, Y., Guo, Y. and Liu, L. (2019) Downregulated IGFBP7 Facilitates Liver Metastasis by Modulating Epithelial-Mesenchymal Transi-tion in Colon Cancer. Oncology Reports, 42, 1935-1945. [Google Scholar] [CrossRef] [PubMed]
[23] Ruan, W., Wang, Y., Ma, Y., Xing, X., Lin, J., Cui, J. and Lai, M. (2010) HSP60, a Protein Downregulated by IGFBP7 in Colorectal Carcinoma. Journal of Experimental & Clinical Can-cer Research, 29, Article No. 41. [Google Scholar] [CrossRef] [PubMed]
[24] Lin, J., Lai, M., Huang, Q., Ma, Y., Cui, J. and Ruan, W. (2007) Methylation Patterns of IGFBP7 in Colon Cancer Cell Lines Are Associated with Levels of Gene Expression. The Jour-nal of Pathology, 212, 83-90. [Google Scholar] [CrossRef] [PubMed]
[25] Suzuki, H., Igarashi, S., Nojima, M., Maruyama, R., Yamamoto, E., Kai, M., Akashi, H., Watanabe, Y., Yamamoto, H., Sasaki, Y., Itoh, F., Imai, K., Sugai, T., Shen, L., Issa, J.P., Shinomura, Y., Tokino, T. and Toyota, M. (2010) IGFBP7 Is a p53-Responsive Gene Specifically Silenced in Colorectal Cancer with CpG Island Methylator Phenotype. Carcinogenesis, 31, 342-349. [Google Scholar] [CrossRef] [PubMed]
[26] Rao, C., Lin, S.-L., Ruan, W.-J., Wen, H., Wu, D.-J. and Deng, H. (2014) High Expression of IGFBP7 in Fibroblasts In-duced by Colorectal Cancer Cells Is Co-Regulated by TGF-β and Wnt Signaling in a Smad2/3-Dvl2/3-Dependent Man-ner. PLOS ONE, 9, e85340. [Google Scholar] [CrossRef] [PubMed]
[27] Zhu, S., Zhang, J., Xu, F., Xu, E., Ruan, W., Ma, Y., Huang, Q. and Lai, M. (2015) IGFBP-rP1 Suppresses Epithelial-Mesenchymal Transition and Me-tastasis in Colorectal Cancer. Cell Death & Disease, 6, e1695. [Google Scholar] [CrossRef] [PubMed]
[28] Qiu, B., Chu, L.Y., Li, X.X., Peng, Y.H., Xu, Y.W., Xie, J.J. and Chen, X.Y. (2020) Diagnostic Value of Serum Insulin-Like Growth Factor Binding Protein 7 (IGFBP7) in Colorectal Cancer. OncoTargets and Therapy, 13, 12131- 12139. [Google Scholar] [CrossRef] 
[29] Chen, D., Yoo, B.K., Santhekadur, P.K., Gredler, R., Bhutia, S.K., Das, S.K., Fuller, C., Su, Z.Z., Fisher, P.B. and Sarkar, D. (2011) Insulin-Like Growth Factor-Binding Protein-7 Functions as a Potential Tumor Suppressor in Hepatocellular Carcinoma. Clinical Cancer Research, 17, 6693-6701. [Google Scholar] [CrossRef] 
[30] Tomimaru, Y., Eguchi, H., Wada, H., Kobayashi, S., Marubashi, S., Tanemura, M., Umeshita, K., Kim, T., Wakasa, K., Doki, Y., Mori, M. and Nagano, H. (2012) IGFBP7 Downregulation Is Associated with Tumor Progression and Clinical Outcome in Hepatocellular Carcinoma. International Journal of Cancer, 130, 319-327. [Google Scholar] [CrossRef] [PubMed]
[31] Li, F., Fan, Y.-C., Gao, S., Sun, F.-K., Yang, Y. and Wang, K. (2014) Methylation of Serum Insulin-Like Growth Factor-Binding Protein 7 Promoter in Hepatitis B Virus-Associated Hepato-cellular Carcinoma. Genes, Chromosomes and Cancer, 53, 90-97. [Google Scholar] [CrossRef] [PubMed]
[32] Chen, D., Siddiq, A., Emdad, L., Rajasekaran, D., Gredler, R., Shen, X.N., Santhekadur, P.K., Srivastava, J., Robertson, C.L., Dmitriev, I., Kashentseva, E.A., Curiel, D.T., Fisher, P.B. and Sarkar, D. (2023) Retraction Notice to: Insulin-Like Growth Factor-Binding Protein-7 (IGFBP7): A Promising Gene Therapeutic for Hepatocellular Carcinoma (HCC). Mo-lecular Therapy, 31, 599. [Google Scholar] [CrossRef] [PubMed]
[33] Brindley, P.J., Bachini, M., Ilyas, S.I., Khan, S.A., Loukas, A., Sirica, A.E., Teh, B.T., Wongkham, S. and Gores, G.J. (2021) Cholangiocarcinoma. Nature Re-views Disease Primers, 7, Article No. 65. [Google Scholar] [CrossRef] [PubMed]
[34] Yue, C., Yang, M., Tian, Q., Mo, F., Peng, J., Ma, Y., Huang, Y., Wang, D., Wang, Y. and Hu, Z. (2018) IGFBP7 Is Associated to Prognosis and Could Suppress Cell Survival in Cholangiocarcinoma. Artificial Cells, Nanomedicine, and Biotechnology, 46, 817-825. [Google Scholar] [CrossRef] [PubMed]
[35] Hu, J.-X., Zhao, C.-F., Chen, W.-B., Liu, Q.-C., Li, Q.-W., Lin, Y.-Y. and Gao, F. (2021) Pancreatic Cancer: A Review of Epidemiology, Trend, and Risk Factors. World Journal of Gastroenterology, 27, 4298-4321. [Google Scholar] [CrossRef] [PubMed]
[36] An, W., Ben, Q.-W., Chen, H.-T., Zheng, J.-M., Huang, L., Li, G.-X. and Li, Z.-S. (2012) Low Expression of IGFBP7 Is Associated with Poor Outcome of Pancreatic Ductal Adeno-carcinoma. Annals of Surgical Oncology, 19, 3971-3978. [Google Scholar] [CrossRef] [PubMed]

为你推荐